Skip to main content

Table 1 Baseline characteristics of study participants (n = 75)

From: Treatment adherence and health outcomes in patients with bronchiectasis

Characteristic Result
Age, yr 64 ± 8
Gender, M/F 24 (32)/51 (68)
Occupational status, n (%) Employed/self-employed 18 (24)
  Retired 57 (76)
Level of education, n (%) Less than high school 14 (19)
  High school 54 (72)
  University 7 (9)
Marital status, n (%) Married or with a partner 57 (76)
  Not married or not with a partner 18 (24)
FEV1, L 1.34 ± 0.6
FEV1,% predicted 61 ± 25
Smoking status, n (%) Never 53 (71%)
  Current or ex 22 (29%)
Aetiology, n (%) Post-infection 32 (43%)
  Idiopathic 16 (21%)
  Rheumatoid arthritis 8 (11%)
  COPD 5 (7%)
  Asthma 3 (4%)
  Other 11 (15%)
Prescribed medicines   12 ± 5
Inhaled antibiotics, n (%) Colistin 64 (85%)
  Tobramycin 11 (15%)
Other respiratory medicines, n (%)   
Oral medicines Azithromycin 38 (51%)
  Oral steroids 19 (25%)
  Mucolytics 10 (13%)
  Leukotriene receptor antagonists 8 (11%)
  Theophylline 7 (9%)
  Co-trimoxazole 1 (1%)
  Salbutamol 1 (1%)
Inhaled medicines Short-acting beta2 agonists 67 (89%)
  Inhaled corticosteroids 65 (87%)
  Antimuscarinics 31 (41%)
  Long-acting beta2 agonists 2 (3%)
Nebulised medicines Short-acting beta2 agonists 55 (73%)
  Isotonic saline 25 (33%)
  Ipratropium bromide with salbutamol 3 (4%)
  Hypertonic saline 1 (1%)
  Budesonide 1 (1%)
Airway clearance Active cycle of breathing technique 39 (53%)
  Acapella® 45 (61%)
QOL-B Physical functioning 31 ± 26
  Role functioning 45 ± 28
  Vitality functioning 37 ± 20
  Social functioning 42 ± 26
  Emotional functioning 73 ± 21
  Treatment burden 56 ± 20
  Health perceptions 39 ± 19
  Respiratory symptoms 53 ± 21
  1. Results are presented as mean ± SD or n (%).
  2. COPD: chronic obstructive pulmonary disease.
  3. QOL-B: Quality of Life Questionnaire-Bronchiectasis; scores range 0–100, higher scores indicate better quality of life.